AR116905A1 - Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolor - Google Patents
Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolorInfo
- Publication number
- AR116905A1 AR116905A1 ARP190103622A ARP190103622A AR116905A1 AR 116905 A1 AR116905 A1 AR 116905A1 AR P190103622 A ARP190103622 A AR P190103622A AR P190103622 A ARP190103622 A AR P190103622A AR 116905 A1 AR116905 A1 AR 116905A1
- Authority
- AR
- Argentina
- Prior art keywords
- radical
- unbranched
- branched
- hydrogen atom
- independently
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 12
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 abstract 3
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se refiere a compuestos que muestran actividad farmacológica dual respecto a la subunidad a2d de canales de calcio dependientes de voltaje (VGCC), especialmente la subunidad a2d-1 de canales de calcio dependientes de voltaje, y el receptor de opioides m (MOR o mu-opioide). La presente también se refiere al proceso para la preparación de dichos compuestos, así como también a las composiciones que los comprenden y su uso como medicamentos. Reivindicación 1: Un compuesto de fórmula general (1), donde: W¹ es -O-, -NRᵃ o -CH₂-; Rᵃ es un átomo de hidrógeno o un radical alquilo C₁₋₆ ramificado o no ramificado; n y m son independientemente el uno del otro 0 ó 1; R¹, R² y R⁴ son independientemente el uno del otro un átomo de hidrógeno; un radical alquilo C₁₋₆ ramificado o no ramificado; un átomo de halógeno; un radical C(O)H; un radical alcoxi C₁₋₆ ramificado o no ramificado; un radical -NRᵇRᶜ; un radical -CN; un radical hidroxilo; o un radical haloalquilo C₁₋₆; Rᵇ y Rᶜ son independientemente el uno del otro un átomo de hidrógeno o un radical alquilo C₁₋₆ ramificado o no ramificado; R³ se selecciona entre: los compuestos de fórmula (2) y (3); W² es -C(O)-, -CH₂- o un enlace; A es C o N; la línea discontinua representa un doble enlace opcional; R³ᵃ y R³ᵇ son independientemente el uno del otro un átomo de hidrógeno o un radical alquilo C₁₋₆ ramificado o no ramificado; o R³ᵃ y R³ᵇ junto con el nitrógeno puente forman un radical heterocicloalquilo de 4, 5 ó 6 miembros que contiene opcionalmente un heteroátomo adicional seleccionado entre N, O y S sustituido opcionalmente con un radical alquilo C₁₋₆ ramificado o no ramificado o un radical alcoxi C₁₋₆ ramificado o no ramificado; R³ᶜ es un átomo de hidrógeno; un átomo de halógeno; un radical hidroxilo; un radical alquilo C₁₋₆ ramificado o no ramificado; un radical alcoxi C₁₋₆ ramificado o no ramificado; un radical -CN; un radical haloalquilo C₁₋₆; o un radical -NR³ᶜR³ᵈ; R³ᵈ y R³ᵉ son independientemente el uno del otro un átomo de hidrógeno o un radical alquilo C₁₋₆ ramificado o no ramificado; R⁵ es un átomo de hidrógeno o un radical -C(O)R⁵ᵃ; R⁵ᵃ es un átomo de hidrógeno; un radical alquilo C₁₋₆ ramificado o no ramificado; un radical alcoxi C₁₋₆ ramificado o no ramificado; un radical -(CH₂)ʳ-NR⁵ᵇR⁵ᶜ; un radical -OCH(CH₃)OC(O)CH(CH₃)₂; o un radical -NR⁵ᵍ-(CH₂)ₛ-CH(R⁵ᶠ)-NR⁵ᵉR⁵ᵈ; r es 1, 2, 3, 4, 5 ó 6; s es 1, 2, 3, 4, 5 ó 6; R⁵ᵇ, R⁵ᶜ, R⁵ᵈ, R⁵ᵉ, R⁵ᵍ son independientemente unos de otros un átomo de hidrógeno; o un radical alquilo C₁₋₆ ramificado o no ramificado; R⁵ᶠ es un átomo de hidrógeno o un radical -COR⁵ʰ; R⁵ʰ es un radical hidroxilo o un radical alquilo C₁₋₆ ramificado o no ramificado; R⁶ es un radical -C(O)R⁶ᵃ; un anillo heteroarilo de 5 ó 6 miembros sustituido opcionalmente que contiene al menos un heteroátomo seleccionado entre N, O y S; R⁶ᵃ es un radical hidroxilo, un radical alcoxi C₁₋₆ ramificado o no ramificado; un radical -(CH₂)ₜ-NR⁶ᵇR⁶ᶜ; un radical -OCH(CH₃)OC(O)CH(CH₃)₂; o un radical -NR⁶ᵍ-(CH₂)ᵛCH(R⁶ᶠ)-NR⁶ᵉR⁶ᵈ; t es 1, 2, 3, 4, 5 ó 6; v es 1, 2, 3, 4, 5 ó 6; R⁶ᵇ, R⁶ᶜ, R⁶ᵈ, R⁶ᵉ, R⁶ᵍ son independientemente unos de otros un átomo de hidrógeno; o un radical alquilo C₁₋₆ ramificado o no ramificado; R⁶ᶠ es un átomo de hidrógeno o un radical -COR⁶ʰ; R⁶ʰ es un radical hidroxilo o un radical alquilo C₁₋₆ ramificado o no ramificado; o una sal, isómero, profármaco o solvato farmacéuticamente aceptable de estos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382915 | 2018-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR116905A1 true AR116905A1 (es) | 2021-06-23 |
Family
ID=64746482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103622A AR116905A1 (es) | 2018-12-12 | 2019-12-11 | Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolor |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR116905A1 (es) |
| TW (1) | TW202026281A (es) |
| WO (1) | WO2020120539A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR112463A1 (es) * | 2017-07-27 | 2019-10-30 | Esteve Pharmaceuticals Sa | Derivados de propanamina para tratar el dolor y estados relacionados con dolor |
| CN115190815B (zh) | 2019-12-26 | 2024-06-18 | 吉尔伽美什制药公司 | 芳基环己基胺衍生物及其在精神障碍的治疗中的用途 |
| WO2021168082A1 (en) | 2020-02-18 | 2021-08-26 | Gilgamesh Pharmaceuticals, Inc. | Specific tryptamines for use in the treatment of mood disorders |
| US12129234B1 (en) | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| US12157722B1 (en) | 2023-08-03 | 2024-12-03 | Gilgamesh Pharmaceuticals, Inc. | Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0225379D0 (en) * | 2002-10-31 | 2002-12-11 | Pfizer Ltd | Therapeutic proline derivatives |
| DE10252666A1 (de) * | 2002-11-11 | 2004-08-05 | Grünenthal GmbH | N-Piperidyl-cyclohexan-Derivate |
| WO2004043900A2 (de) * | 2002-11-12 | 2004-05-27 | Grünenthal GmbH | 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate |
-
2019
- 2019-12-03 TW TW108144189A patent/TW202026281A/zh unknown
- 2019-12-11 AR ARP190103622A patent/AR116905A1/es unknown
- 2019-12-11 WO PCT/EP2019/084577 patent/WO2020120539A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| TW202026281A (zh) | 2020-07-16 |
| WO2020120539A1 (en) | 2020-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116905A1 (es) | Derivados de ácido pirrolidino-2-carboxílico para tratar el dolor y afecciones relacionadas con el dolor | |
| AR108709A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR107616A1 (es) | Compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| AR119943A1 (es) | Compuestos heterocíclicos | |
| AR098721A1 (es) | Inhibidores de biarilo de tirosina quinasa de bruton | |
| AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR099367A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
| AR120697A1 (es) | Inhibidores de braf como rompedores de la paradoja | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR119910A1 (es) | DERIVADOS DE 4,4a,5,7,8,8a-HEXAHIDROPIRIDO[4,3-b][1,4]OXAZIN-3-ONA COMO INHIBIDORES DE MAGL | |
| AR105522A1 (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor | |
| AR102731A1 (es) | Compuestos espiroisoquinolin-1,4-piperidínicos con actividad multimodal contra el dolor | |
| AR112907A1 (es) | Pirazoles inhibidores de monoacilglicerol lipasa (magl) | |
| PE20190980A1 (es) | Compuestos terapeuticos y metodos para utilizarlos | |
| AR115464A1 (es) | Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tau | |
| AR111271A1 (es) | Inhibidores dobles de magl y faah | |
| AR116464A1 (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| AR131158A1 (es) | Compuestos que inhiben la pkmyt1 | |
| AR123435A1 (es) | Derivados de sulfamoil urea que contienen resto alquilo-oxacicloalquilo, y usos de los mismos | |
| AR122703A1 (es) | Inhibidores de rip1k | |
| AR128440A1 (es) | Inhibidores de cinasas raf | |
| AR119341A1 (es) | Profármacos de moduladores del receptor de nmda | |
| AR112463A1 (es) | Derivados de propanamina para tratar el dolor y estados relacionados con dolor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |